Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker VKTX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | Brian Lian President & CEO, Director | VKTX Viking Therapeutics, Inc. | Sale | 148,517 | $33.32 | $4.9M Sale | Form 4 ↗ |
| Jul 29, 2026 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 21,217 | $33.47 | $710.1K Sale | Form 4 ↗ |
| Jul 29, 2026 | Marianna Mancini Chief Operating Officer | VKTX Viking Therapeutics, Inc. | Sale | 18,217 | $33.47 | $609.7K Sale | Form 4 ↗ |
| Mar 10, 2026 | Neil William Aubuchon Chief Commercial Officer | VKTX Viking Therapeutics, Inc. | Buy | 4,475 | $33.50 | $149.9K Buy | Form 4 ↗ |
| Jan 5, 2026 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 1,500 | $32.09 | $48.1K Sale | Form 4 ↗ |
| Jan 5, 2026 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 10,300 | $34.24 | $352.7K Sale | Form 4 ↗ |
| Jan 5, 2026 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 13,900 | $33.38 | $464.0K Sale | Form 4 ↗ |
| Jan 5, 2026 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 31,961 | $32.30 | $1.0M Sale | Form 4 ↗ |
| Jan 5, 2026 | Marianna Mancini Chief Operating Officer | VKTX Viking Therapeutics, Inc. | Sale | 1,600 | $35.07 | $56.1K Sale | Form 4 ↗ |
| Jan 5, 2026 | Marianna Mancini Chief Operating Officer | VKTX Viking Therapeutics, Inc. | Sale | 10,500 | $34.22 | $359.3K Sale | Form 4 ↗ |
| Jan 5, 2026 | Marianna Mancini Chief Operating Officer | VKTX Viking Therapeutics, Inc. | Sale | 13,600 | $33.37 | $453.8K Sale | Form 4 ↗ |
| Jan 5, 2026 | Marianna Mancini Chief Operating Officer | VKTX Viking Therapeutics, Inc. | Sale | 31,961 | $32.29 | $1.0M Sale | Form 4 ↗ |
| Jan 5, 2026 | Brian Lian President & CEO, Director | VKTX Viking Therapeutics, Inc. | Sale | 6,400 | $35.07 | $224.4K Sale | Form 4 ↗ |
| Jan 5, 2026 | Brian Lian President & CEO, Director | VKTX Viking Therapeutics, Inc. | Sale | 41,276 | $34.22 | $1.4M Sale | Form 4 ↗ |
| Jan 5, 2026 | Brian Lian President & CEO, Director | VKTX Viking Therapeutics, Inc. | Sale | 53,279 | $33.38 | $1.8M Sale | Form 4 ↗ |
| Jan 5, 2026 | Brian Lian President & CEO, Director | VKTX Viking Therapeutics, Inc. | Sale | 132,454 | $32.29 | $4.3M Sale | Form 4 ↗ |
| Jan 2, 2026 | Matthew W. Foehr Director | VKTX Viking Therapeutics, Inc. | Sale | 16,000 | $35.11 | $561.8K Sale | Form 4 ↗ |
| Oct 28, 2025 | Marianna Mancini Chief Operating Officer | VKTX Viking Therapeutics, Inc. | Sale | 6,185 | $35.00 | $216.5K Sale | Form 4 ↗ |
| Oct 28, 2025 | Brian Lian President & CEO, Director | VKTX Viking Therapeutics, Inc. | Sale | 38,989 | $35.01 | $1.4M Sale | Form 4 ↗ |
| Oct 28, 2025 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 6,185 | $35.00 | $216.5K Sale | Form 4 ↗ |
| Oct 27, 2025 | Charles A. Rowland Jr. Director | VKTX Viking Therapeutics, Inc. | Sale | 60,000 | $35.57 | $2.1M Sale | Form 4 ↗ |
| Jul 3, 2025 | Brian Lian President & CEO, Director | VKTX Viking Therapeutics, Inc. | Sale | 26,889 | $27.80 | $747.5K Sale | Form 4 ↗ |
| Jul 3, 2025 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 4,266 | $27.76 | $118.4K Sale | Form 4 ↗ |
| Jul 3, 2025 | Marianna Mancini Chief Operating Officer | VKTX Viking Therapeutics, Inc. | Sale | 4,266 | $27.77 | $118.5K Sale | Form 4 ↗ |
| Mar 31, 2025 | Sarah Kathryn Rouan Director | VKTX Viking Therapeutics, Inc. | Buy | 1,240 | $24.15 | $29.9K Buy | Form 4/A ↗ |
| Jan 6, 2025 | Brian Lian President & CEO, Director | VKTX Viking Therapeutics, Inc. | Sale | 19,000 | $43.32 | $823.1K Sale | Form 4 ↗ |
| Jan 6, 2025 | Brian Lian President & CEO, Director | VKTX Viking Therapeutics, Inc. | Sale | 175,490 | $42.68 | $7.5M Sale | Form 4 ↗ |
| Jan 6, 2025 | Marianna Mancini Chief Operating Officer | VKTX Viking Therapeutics, Inc. | Sale | 5,100 | $43.32 | $220.9K Sale | Form 4 ↗ |
| Jan 6, 2025 | Marianna Mancini Chief Operating Officer | VKTX Viking Therapeutics, Inc. | Sale | 49,115 | $42.69 | $2.1M Sale | Form 4 ↗ |
| Jan 6, 2025 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 4,700 | $43.32 | $203.6K Sale | Form 4 ↗ |
| Jan 6, 2025 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 45,609 | $42.69 | $1.9M Sale | Form 4 ↗ |
| Nov 8, 2024 | Lawson Macartney Director | VKTX Viking Therapeutics, Inc. | Sale | 2,000 | $68.67 | $137.3K Sale | Form 4 ↗ |
| Oct 28, 2024 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 1,206 | $81.44 | $98.2K Sale | Form 4 ↗ |
| Oct 28, 2024 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 7,967 | $80.65 | $642.5K Sale | Form 4 ↗ |
| Oct 28, 2024 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 6,050 | $79.78 | $482.7K Sale | Form 4 ↗ |
| Oct 28, 2024 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 15,825 | $78.69 | $1.2M Sale | Form 4 ↗ |
| Oct 28, 2024 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 23,082 | $77.68 | $1.8M Sale | Form 4 ↗ |
| Oct 28, 2024 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 9,265 | $76.94 | $712.8K Sale | Form 4 ↗ |
| Oct 28, 2024 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 18,620 | $75.79 | $1.4M Sale | Form 4 ↗ |
| Oct 28, 2024 | Greg Zante Chief Financial Officer | VKTX Viking Therapeutics, Inc. | Sale | 49,672 | $74.56 | $3.7M Sale | Form 4 ↗ |
| Oct 25, 2024 | Sarah Kathryn Rouan Director | VKTX Viking Therapeutics, Inc. | Sale | 11,000 | $80.89 | $889.8K Sale | Form 4 ↗ |
| Oct 25, 2024 | J. Matthew Singleton Director | VKTX Viking Therapeutics, Inc. | Sale | 16,000 | $79.50 | $1.3M Sale | Form 4 ↗ |
42 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 7:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances